Akash Malhotra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akash Malhotra has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Hojoon Sohn
Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
3 shared publications Amido Charama
Comité para Saúde de Moçambique, Maputo, Mozambique
2 shared publicationsAna Olga Mocumbi
Department of Global Health, University of Washington, Seattle, WA, USA
2 shared publicationsCarmen Hazim
Department of Global Health, University of Washington, Seattle, WA, USA
2 shared publicationsDavid Watkins
Department of Global Health, University of Washington, Seattle, WA, USA
2 shared publicationsIsaias Ramiro
Comité para Saúde de Moçambique, Maputo, Mozambique
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (9)
Cost-effectiveness of providing pre-exposure and post-exposure prophylaxis for the prevention of HIV via online pharmacies in western Kenya: a modelling study
- 7 August 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (9)
Open AccessCost-effectiveness of providing pre-exposure and post-exposure prophylaxis for the prevention of HIV via online pharmacies in western Kenya: a modelling study
- Open Access
- 25 February 2026
- Published by Springer Nature in Implementation Science Communications
- Vol. 7 (1)
Mathematical modeling to assess health and economic impact of cardiovascular interventions and implementation strategies among people living with HIV: SAIA HTN
Background: Few economic evaluations distinguish between the cost and impact of evidence-based interventions and the strategies used to improve their implementation. This distinction is essential for understanding whether a strategy is cost-effective, why it works, and the resources required to replicate its success. The Systems Analysis and Improvement Approach Hypertension (SAIA-HTN) trial evaluated an implementation strategy (“SAIA”) designed to improve hypertension care among people living with HIV (PLHIV) in Mozambique. We developed a mathematical model to estimate the cost-effectiveness of both the evidence-based intervention (including hypertension screening, pharmacological treatment and follow up, and lifestyle modifications such as diet and exercise) and the SAIA implementation strategy. Methods: We constructed a decision-analytic, state-transition model that simulated cardiovascular risk, outcomes, and associated costs for PLHIV receiving hypertension care in Mozambique using a health systems perspective. Model inputs came from published epidemiological studies and primary data from the SAIA-HTN trial on intervention and implementation strategy effectiveness and costs. We estimated the incremental cost-effectiveness (willingness to pay $647/DALY averted, GDP per capita in Mozambique) of rolling out both components, compared to a “status quo” scenario where screening and treatment of hypertension remained at their current (very low) levels. Costs were reported in 2023 US dollars, and costs and outcomes were discounted at 3% over a ten-year time horizon. Results: Scaling up screening and pharmacological treatment of hypertension in Mozambique would have an incremental cost-effectiveness ratio (ICER) of around $212 per disability-adjusted life year (DALY) averted and cost an additional $4.61 per person per year. Incremental to the intervention, the SAIA implementation strategy would have an ICER of $44 per DALY averted and cost an additional $0.79 per person per year. The average reduction in ten-year cardiovascular risk would be 29.3% for the intervention and 40.3% if the SAIA implementation strategy were co-introduced. Conclusions: Our model is a tool for implementation scientists, policymakers, and researchers aiming to assess cardiovascular interventions and associated implementation strategies among PLHIV. Its application to SAIA-HTN suggests that this is a cost-effective strategy for improving hypertension care, but only in the presence of adequate blood pressure equipment, training, and medications. Our study shows how implementation strategies require a minimum threshold of health system readiness to generate meaningful health impact. Trial registration: ClinicalTrials.gov (NCT04088656).
- 25 February 2026
- Published by Springer Nature in Implementation Science Communications
- Vol. 7 (1)
Open AccessMathematical modeling to assess health and economic impact of cardiovascular interventions and implementation strategies among people living with HIV: SAIA HTN
Background: Few economic evaluations distinguish between the cost and impact of evidence-based interventions and the strategies used to improve their implementation. This distinction is essential for understanding whether a strategy is cost-effective, why it works, and the resources required to replicate its success. The Systems Analysis and Improvement Approach Hypertension (SAIA-HTN) trial evaluated an implementation strategy (“SAIA”) designed to improve hypertension care among people living with HIV (PLHIV) in Mozambique. We developed a mathematical model to estimate the cost-effectiveness of both the evidence-based intervention (including hypertension screening, pharmacological treatment and follow up, and lifestyle modifications such as diet and exercise) and the SAIA implementation strategy. Methods: We constructed a decision-analytic, state-transition model that simulated cardiovascular risk, outcomes, and associated costs for PLHIV receiving hypertension care in Mozambique using a health systems perspective. Model inputs came from published epidemiological studies and primary data from the SAIA-HTN trial on intervention and implementation strategy effectiveness and costs. We estimated the incremental cost-effectiveness (willingness to pay $647/DALY averted, GDP per capita in Mozambique) of rolling out both components, compared to a “status quo” scenario where screening and treatment of hypertension remained at their current (very low) levels. Costs were reported in 2023 US dollars, and costs and outcomes were discounted at 3% over a ten-year time horizon. Results: Scaling up screening and pharmacological treatment of hypertension in Mozambique would have an incremental cost-effectiveness ratio (ICER) of around $212 per disability-adjusted life year (DALY) averted and cost an additional $4.61 per person per year. Incremental to the intervention, the SAIA implementation strategy would have an ICER of $44 per DALY averted and cost an additional $0.79 per person per year. The average reduction in ten-year cardiovascular risk would be 29.3% for the intervention and 40.3% if the SAIA implementation strategy were co-introduced. Conclusions: Our model is a tool for implementation scientists, policymakers, and researchers aiming to assess cardiovascular interventions and associated implementation strategies among PLHIV. Its application to SAIA-HTN suggests that this is a cost-effective strategy for improving hypertension care, but only in the presence of adequate blood pressure equipment, training, and medications. Our study shows how implementation strategies require a minimum threshold of health system readiness to generate meaningful health impact. Trial registration: ClinicalTrials.gov (NCT04088656).
- Open Access
- 30 May 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (5) , e0004724
Decentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania: a cost and cost-effectiveness analysis
In low-and middle-income countries, missed or delayed tuberculosis (TB) diagnoses contribute to avoidable morbidity, mortality, and transmission. Decentralized testing platforms, such as the Molbio Truenat, may offer solutions by providing accurate point-of-care testing, improving access, and lowering out-of-pocket costs. Despite these advantages, the overall cost and cost-effectiveness of identifying additional TB cases using the Truenat MTB assays remain inadequately explored and understood. We collected economic data from a multicentre randomized controlled trial of TB testing using decentralized Molbio Truenat platform with MTB Plus and MTB-RIF Dx assays (Truenat MTB assays) versus hub-and-spoke Xpert MTB/RIF Ultra (standard of care) in Tanzania and Mozambique (TB-CAPT Core trial). We estimated facility-based diagnostic cost per participant tested and incremental facility-based diagnostic cost per incremental participant initiating TB treatment within seven and sixty days from enrolment. We used the societal perspective and conducted sensitivity analyses to determine key drivers of cost-effectiveness. The facility-based diagnostic cost per participant initiating treatment within seven days from enrolment in Mozambique was $853(95% uncertainty range: $707, $1072) for hub-and-spoke testing and $690($588, $823) for decentralized testing; in Tanzania costs were $596($485, $746) for hub-and-spoke testing and $592($495, $715) for decentralized testing. At sixty days, costs per treatment initiation were $581($493, $706) for hub-and-spoke vs. $678($576, $811) for decentralized testing in Mozambique, and $391($324, $476) vs. $591($494, $716) in Tanzania. Comparing decentralized to hub-and-spoke testing, the incremental cost per incremental seven-day treatment initiation was $403(-$103, $941) in Mozambique and $580($167, $1638) in Tanzania, and $805(-$10107, $10560) and -$353(-$20299, $20802) for sixty-day treatment initiation, respectively. Utilization (i.e., testing volume) of decentralized equipment was the strongest driver of cost-effectiveness. Decentralized TB testing with Truenat MTB assays is cost-effective relative to hub-and-spoke testing in Mozambique and Tanzania.
- 30 May 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (5) , e0004724
Open AccessDecentralized TB diagnostic testing with Truenat MTB Plus and MTB-RIF Dx vs. hub-and-spoke GeneXpert MTB/RIF Ultra in Mozambique and Tanzania: a cost and cost-effectiveness analysis
In low-and middle-income countries, missed or delayed tuberculosis (TB) diagnoses contribute to avoidable morbidity, mortality, and transmission. Decentralized testing platforms, such as the Molbio Truenat, may offer solutions by providing accurate point-of-care testing, improving access, and lowering out-of-pocket costs. Despite these advantages, the overall cost and cost-effectiveness of identifying additional TB cases using the Truenat MTB assays remain inadequately explored and understood. We collected economic data from a multicentre randomized controlled trial of TB testing using decentralized Molbio Truenat platform with MTB Plus and MTB-RIF Dx assays (Truenat MTB assays) versus hub-and-spoke Xpert MTB/RIF Ultra (standard of care) in Tanzania and Mozambique (TB-CAPT Core trial). We estimated facility-based diagnostic cost per participant tested and incremental facility-based diagnostic cost per incremental participant initiating TB treatment within seven and sixty days from enrolment. We used the societal perspective and conducted sensitivity analyses to determine key drivers of cost-effectiveness. The facility-based diagnostic cost per participant initiating treatment within seven days from enrolment in Mozambique was $853(95% uncertainty range: $707, $1072) for hub-and-spoke testing and $690($588, $823) for decentralized testing; in Tanzania costs were $596($485, $746) for hub-and-spoke testing and $592($495, $715) for decentralized testing. At sixty days, costs per treatment initiation were $581($493, $706) for hub-and-spoke vs. $678($576, $811) for decentralized testing in Mozambique, and $391($324, $476) vs. $591($494, $716) in Tanzania. Comparing decentralized to hub-and-spoke testing, the incremental cost per incremental seven-day treatment initiation was $403(-$103, $941) in Mozambique and $580($167, $1638) in Tanzania, and $805(-$10107, $10560) and -$353(-$20299, $20802) for sixty-day treatment initiation, respectively. Utilization (i.e., testing volume) of decentralized equipment was the strongest driver of cost-effectiveness. Decentralized TB testing with Truenat MTB assays is cost-effective relative to hub-and-spoke testing in Mozambique and Tanzania.
- Open Access
- 30 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004466
Cost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)
Tuberculosis preventive treatment (TPT) is an essential intervention recommended for all child contacts in Ethiopia under 15 years who are at risk of tuberculosis (TB) infection. We conducted a cost and cost-effectiveness analysis of home-based versus facility-based TPT provision for child contacts in Ethiopia. As part of the CHIP TB trial, a pragmatic, cluster-randomized trial conducted at eighteen clinics in Ethiopia, clinics were randomized to either a home-based model (intervention arm), administered by community health workers, or a facility-based model (standard of care) for managing child contacts. Cost data were collected from both a health service perspective and a household perspective, capturing all costs relevant to TPT. Costs were evaluated on a per-household basis, with the primary outcome being the difference in median costs per household initiating TPT. A secondary outcome assessed the cost-effectiveness as the incremental cost per additional child contact starting TPT. Probabilistic sensitivity analyses (PSA) were conducted to examine the robustness of findings. At an average cost of US$18.92 per household managed, Home-based contact management, including TPT delivery was cost-saving compared to facility-based TPT delivery (US$27.24 per household managed) assessed based on the partial-societal perspectives, largely due to reductions in household out-of-pocket costs. The home-based strategy was both less costly and had increased TPT initiation in 61.5% of the scenarios assessed in the PSA. Home-based contact management is a cost-saving alternative for households and provides comparable initiation rates to facility-based care, making it a feasible approach to improve TB preventive treatment accessibility. Although it does not entirely replace facility-based care, a hybrid model that respects household preferences and allows flexibility in delivery could enhance TB care access for socio-economically disadvantaged households, potentially reducing health inequities. The trial was registered on clinicaltrials.gov NCT04369326 on April 30, 2020. https://clinicaltrials.gov/study/NCT04369326.
- 30 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004466
Open AccessCost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)
Tuberculosis preventive treatment (TPT) is an essential intervention recommended for all child contacts in Ethiopia under 15 years who are at risk of tuberculosis (TB) infection. We conducted a cost and cost-effectiveness analysis of home-based versus facility-based TPT provision for child contacts in Ethiopia. As part of the CHIP TB trial, a pragmatic, cluster-randomized trial conducted at eighteen clinics in Ethiopia, clinics were randomized to either a home-based model (intervention arm), administered by community health workers, or a facility-based model (standard of care) for managing child contacts. Cost data were collected from both a health service perspective and a household perspective, capturing all costs relevant to TPT. Costs were evaluated on a per-household basis, with the primary outcome being the difference in median costs per household initiating TPT. A secondary outcome assessed the cost-effectiveness as the incremental cost per additional child contact starting TPT. Probabilistic sensitivity analyses (PSA) were conducted to examine the robustness of findings. At an average cost of US$18.92 per household managed, Home-based contact management, including TPT delivery was cost-saving compared to facility-based TPT delivery (US$27.24 per household managed) assessed based on the partial-societal perspectives, largely due to reductions in household out-of-pocket costs. The home-based strategy was both less costly and had increased TPT initiation in 61.5% of the scenarios assessed in the PSA. Home-based contact management is a cost-saving alternative for households and provides comparable initiation rates to facility-based care, making it a feasible approach to improve TB preventive treatment accessibility. Although it does not entirely replace facility-based care, a hybrid model that respects household preferences and allows flexibility in delivery could enhance TB care access for socio-economically disadvantaged households, potentially reducing health inequities. The trial was registered on clinicaltrials.gov NCT04369326 on April 30, 2020. https://clinicaltrials.gov/study/NCT04369326.
- 14 February 2024
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 53 (2)
Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis
Background: In settings with large case detection gaps, active case-finding (ACF) may play a critical role in the uberculosis (TB) response. However, ACF is resource intensive, and its effectiveness depends on whether people detected with TB through ACF might otherwise spontaneously resolve or be diagnosed through routine care. We analysed the potential effectiveness of ACF for TB relative to the counterfactual scenario of routine care alone. Methods: We constructed a Markov simulation model of TB natural history, diagnosis, symptoms, ACF and treatment, using a hypothetical reference setting using data from South East Asian countries. We calibrated the model to empirical data using Bayesian methods, and simulated potential 5-year outcomes with an ‘aspirational’ ACF intervention (reflecting maximum possible effectiveness) compared with the standard-of-care outcomes. Results: Under the standard of care, 51% (95% credible interval, CrI: 31%, 75%) of people with prevalent TB at baseline were estimated to be diagnosed and linked to care over 5 years. With aspirational ACF, this increased to 88% (95% CrI: 84%, 94%). Most of this difference represented people who were diagnosed and treated through ACF but experienced spontaneous resolution under standard-of-care. Aspirational ACF was projected to reduce the average duration of TB disease by 12 months (95% CrI: 6%, 18%) and TB-associated disability-adjusted life-years by 71% (95% CrI: 67%, 76%). Conclusion: These data illustrate the importance of considering outcomes in a counterfactual standard of care scenario, as well as trade-offs between overdiagnosis and averted morbidity through earlier diagnosis—not just for TB, but for any disease in which population-based screening is recommended.
- 14 February 2024
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 53 (2)
Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis
Background: In settings with large case detection gaps, active case-finding (ACF) may play a critical role in the uberculosis (TB) response. However, ACF is resource intensive, and its effectiveness depends on whether people detected with TB through ACF might otherwise spontaneously resolve or be diagnosed through routine care. We analysed the potential effectiveness of ACF for TB relative to the counterfactual scenario of routine care alone. Methods: We constructed a Markov simulation model of TB natural history, diagnosis, symptoms, ACF and treatment, using a hypothetical reference setting using data from South East Asian countries. We calibrated the model to empirical data using Bayesian methods, and simulated potential 5-year outcomes with an ‘aspirational’ ACF intervention (reflecting maximum possible effectiveness) compared with the standard-of-care outcomes. Results: Under the standard of care, 51% (95% credible interval, CrI: 31%, 75%) of people with prevalent TB at baseline were estimated to be diagnosed and linked to care over 5 years. With aspirational ACF, this increased to 88% (95% CrI: 84%, 94%). Most of this difference represented people who were diagnosed and treated through ACF but experienced spontaneous resolution under standard-of-care. Aspirational ACF was projected to reduce the average duration of TB disease by 12 months (95% CrI: 6%, 18%) and TB-associated disability-adjusted life-years by 71% (95% CrI: 67%, 76%). Conclusion: These data illustrate the importance of considering outcomes in a counterfactual standard of care scenario, as well as trade-offs between overdiagnosis and averted morbidity through earlier diagnosis—not just for TB, but for any disease in which population-based screening is recommended.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1951. Optimizing implementation of artificial intelligence-informed digital X-ray screening for tuberculosis through an age- and sex-differentiated approach
Computer-aided detection (CAD) using artificial intelligence (AI) to analyze chest radiographs is an important tool for community tuberculosis (TB) screening in high burden countries. Most current algorithms use a universal cut-off score to select individuals for confirmatory TB testing; however, using a tailored cut-off based on client demographics (age and sex) may improve performance. Community-based TB screening was conducted using portable X-ray with CAD (qXR, [Qure.ai, India]) as part of a cluster-randomized trial in Uganda. Individuals scoring above a specified threshold were offered sputum Xpert Ultra testing. This threshold was initially set at 0.5 (range: 0-1) but was later lowered to 0.2 and then 0.1 for research purposes. For clients with scores ≥ 0.1 who did not undergo Xpert testing, we used multiple imputation to infer Xpert-positive status. We assumed that those with X-ray scores < 0.1 would be Xpert-negative if tested, but considered 0.1% or 0.5% prevalence of Xpert-positive TB in sensitivity analysis. We compared the sensitivity and specificity of using a universal screening threshold of 0.5 versus tailored thresholds based on client age and sex. Sensitivity and specificity of different thresholds on computer-aided detection software (qXR) when using digital chest X-ray for detecting pulmonary tuberculosis. Distribution of CAD scores among individuals screened for TB using digital chest radiograph in Uganda (left) and the proportions of individuals with positive and trace sputum Xpert MTB/RIF Ultra results according to CAD score (right). Proportion of individuals with positive sputum Xpert Ultra (including trace) according to age and sex. Using differentiated CAD score thresholds based on client sex could improve the accuracy of digital X-ray for TB screening. Future research should validate these findings in other populations and explore the value of incorporating additional client characteristics into TB screening algorithms. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1951. Optimizing implementation of artificial intelligence-informed digital X-ray screening for tuberculosis through an age- and sex-differentiated approach
Computer-aided detection (CAD) using artificial intelligence (AI) to analyze chest radiographs is an important tool for community tuberculosis (TB) screening in high burden countries. Most current algorithms use a universal cut-off score to select individuals for confirmatory TB testing; however, using a tailored cut-off based on client demographics (age and sex) may improve performance. Community-based TB screening was conducted using portable X-ray with CAD (qXR, [Qure.ai, India]) as part of a cluster-randomized trial in Uganda. Individuals scoring above a specified threshold were offered sputum Xpert Ultra testing. This threshold was initially set at 0.5 (range: 0-1) but was later lowered to 0.2 and then 0.1 for research purposes. For clients with scores ≥ 0.1 who did not undergo Xpert testing, we used multiple imputation to infer Xpert-positive status. We assumed that those with X-ray scores < 0.1 would be Xpert-negative if tested, but considered 0.1% or 0.5% prevalence of Xpert-positive TB in sensitivity analysis. We compared the sensitivity and specificity of using a universal screening threshold of 0.5 versus tailored thresholds based on client age and sex. Sensitivity and specificity of different thresholds on computer-aided detection software (qXR) when using digital chest X-ray for detecting pulmonary tuberculosis. Distribution of CAD scores among individuals screened for TB using digital chest radiograph in Uganda (left) and the proportions of individuals with positive and trace sputum Xpert MTB/RIF Ultra results according to CAD score (right). Proportion of individuals with positive sputum Xpert Ultra (including trace) according to age and sex. Using differentiated CAD score thresholds based on client sex could improve the accuracy of digital X-ray for TB screening. Future research should validate these findings in other populations and explore the value of incorporating additional client characteristics into TB screening algorithms. All Authors: No reported disclosures
- Open Access
- 24 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290496
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Background: Access to drug resistant testing for tuberculosis (TB) remains a challenge in high burden countries. Recently, the World Health Organization approved the use of several moderate complexity automated nucleic acid amplification tests (MC-NAAT) that have performance profiles suitable for placement in a range of TB laboratory tiers to improve drug susceptibility tests (DST) coverage. Methods: We conducted cost analysis of two MC-NAATs with different testing throughput: Lower Throughput (LT, < 24 tests per run) and Higher Throughput (HT, upto 90+ tests per run) for placement in a hypothetical laboratory in a resource limited setting. We used per-test cost as the main indicator to assess 1) drivers of cost by resource types and 2) optimized levels of annual testing volumes for the respective MC-NAATs. Results: The base-case per test cost of $18.52 (range: $13.79 - $40.70) for LT test and $15.37 (range: $9.61 - $37.40) for HT test. Per test cost estimates were most sensitive to the number of testing days per week, followed by equipment costs and TB-specific workloads. In general, HT NAATs were cheaper at all testing volume levels, but at lower testing volumes (less than 2,000 per year) LT tests can be cheaper if the durability of the testing system is markedly better and/or procured equipment costs are lower than that of HT NAAT. Conclusion: Assuming equivalent performance and infrastructural needs, placement strategies for MC-NAATs need to be prioritized by laboratory system’s operational factors, testing demands, and costs.
- 24 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290496
Open AccessDetermining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Background: Access to drug resistant testing for tuberculosis (TB) remains a challenge in high burden countries. Recently, the World Health Organization approved the use of several moderate complexity automated nucleic acid amplification tests (MC-NAAT) that have performance profiles suitable for placement in a range of TB laboratory tiers to improve drug susceptibility tests (DST) coverage. Methods: We conducted cost analysis of two MC-NAATs with different testing throughput: Lower Throughput (LT, < 24 tests per run) and Higher Throughput (HT, upto 90+ tests per run) for placement in a hypothetical laboratory in a resource limited setting. We used per-test cost as the main indicator to assess 1) drivers of cost by resource types and 2) optimized levels of annual testing volumes for the respective MC-NAATs. Results: The base-case per test cost of $18.52 (range: $13.79 - $40.70) for LT test and $15.37 (range: $9.61 - $37.40) for HT test. Per test cost estimates were most sensitive to the number of testing days per week, followed by equipment costs and TB-specific workloads. In general, HT NAATs were cheaper at all testing volume levels, but at lower testing volumes (less than 2,000 per year) LT tests can be cheaper if the durability of the testing system is markedly better and/or procured equipment costs are lower than that of HT NAAT. Conclusion: Assuming equivalent performance and infrastructural needs, placement strategies for MC-NAATs need to be prioritized by laboratory system’s operational factors, testing demands, and costs.